IRIDEX Net Income/Loss 2012-2026 | IRIX
IRIDEX net income/loss from 2012 to 2026. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
|
IRIDEX Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2025 | $-4 |
| 2024 | $-9 |
| 2023 | $-10 |
| 2022 | $-8 |
| 2021 | $-5 |
| 2020 | $-6 |
| 2019 | $-9 |
| 2018 | $-13 |
| 2017 | $-13 |
| 2016 | $-12 |
| 2015 | $0 |
| 2014 | $10 |
| 2013 | $2 |
| 2012 | $1 |
| 2011 | $3 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Laser Systems and Components | $0.017B | $0.053B |
| IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IPG Photonics (IPGP) | United States | $5.404B | 89.66 |
| Applied Energetics (AERG) | United States | $0.246B | 0.00 |